Document is current

Article History

Received: 6 February 2025

Accepted: 28 April 2025

First Online: 29 May 2025

Declarations

:

: AJM reports grants from the ASCO Conquer Cancer Young Investigator Award and a National Institutes of Health K12 grant (K12 CA087723). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Society of Clinical Oncology or the National Institutes of Health. AJM reports personal fees from AstraZeneca, Edgewood Oncology, Guardant Health, Illumina, Myriad Genetics, Natera, Novartis, and research funding from AstraZeneca. LG reports personal fees from Novartis, Eli Lilly, AstraZeneca, Incyte and GlaxoSmithKline. LG reports research funding to the institution from AstraZeneca. AAD reports personal fees from Pfizer and bioTheranostics. WLH reports personal fees from Novartis and Gilead. LMS declares the following relationships: Consultant/advisory board: Novartis, Daiichi Pharma, Astra Zeneca, Eli Lilly, Precede, Seagen; Institutional research support: Merck, Genentech, Gilead, Eli Lilly. LWE reports personal fees from Mersana, KisoJi Biotechnology, Gilead Sciences. RCD is an employee and shareholder of Rain Oncology. MC reports personal fees from Lily, Menarini, Polaris, AstraZeneca/Daiichi Sankyo, Syantra, Sermonix Pharmaceuticals, Celcuity, Pfizer, and research funding from Lilly, Angle, Merck, AstraZeneca, and Menarini Silicon Biosystems. AB reports personal fees from Novartis, Genentech, Pfizer, Merck, Novartis, Genentech/Roche, Radius, Innocrin, Sanofi, AstraZeneca/Daiichi Sankyo, Lilly, Gilead Sciences, Menarini, and Mersana and research funding from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, and AstraZeneca/Daiichi Sankyo. All other authors declare no competing interests.